{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T01:36:09Z","timestamp":1794274569154,"version":"4.9.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2021,6,28]],"date-time":"2021-06-28T00:00:00Z","timestamp":1624838400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,6,28]],"date-time":"2021-06-28T00:00:00Z","timestamp":1624838400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eye"],"published-print":{"date-parts":[[2022,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>In recent trials, 50% of patients treated with teprotumumab for thyroid eye disease had significant improvements in proptosis at 6 weeks. However, a small subgroup of patients did not have a significant response by week 12. We examine the outcomes at week 24 in patients from both trials who had little or no proptosis response at week 12.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Design<\/jats:title>\n                <jats:p>In this post hoc analysis, data from teprotumumab-treated patients in the placebo-controlled randomized phases 2 and 3 trials were reviewed.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Patients treated with teprotumumab or placebo with a \u22642\u2009mm reduction from baseline in proptosis at week 12 and completed assessments at both the weeks 12 and 24 visits were included. The main outcome measures were a change in proptosis, clinical activity score (CAS) and diplopia in response to teprotumumab therapy at baseline and weeks 6, 12, 18, and 24.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>From the phases 2 and 3 studies, 24 patients from the treated and placebo groups were included for analysis (48 total). In the teprotumumab group, of the 24 who had no improvement in proptosis (\u22652\u2009mm from baseline) at 12 weeks, 15 (63%) demonstrated a clinically significant improvement at week 24. No patients from the 24 placebo patients had a clinically significant improvement in proptosis at 12 weeks,\u00a0and 24 weeks. At week 12, 22 patients (92%) in the teprotumumab group had a significant reduction in the CAS (\u22652 points) and at 24 weeks all patients achieved this reduction. At week 12, 11 (46%) patients from the placebo group had a significant improvement, while 10 (42%) had a significant improvement at 24 weeks. 22 of the 24 patients (92%) in the teprotumumab group had a diplopia grade\u2009&gt;\u20090 at baseline. At week 12, 12 of the 22 (55%) had improvement in diplopia\u2009\u2265\u20091 grade. By week 24, 16 patients (73%) had an improvement in diplopia\u2009\u2265\u20091 grade. In the placebo group, 15 (63%) had significant diplopia. At week 12, 3 (20%) from this group had improvement in diplopia\u2009\u2265\u20091 grade, while at 24 weeks this number rose to 4 (27%).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>There is variability in the time taken to manifest a clinically significant response to teprotumumab, some patients my need a longer time to respond.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1038\/s41433-021-01539-5","type":"journal-article","created":{"date-parts":[[2021,6,28]],"date-time":"2021-06-28T08:02:44Z","timestamp":1624867364000},"page":"1403-1408","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Teprotumumab for thyroid eye disease: early response is not required for benefit"],"prefix":"10.1038","volume":"36","author":[{"given":"Shoaib","family":"Ugradar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tunde","family":"Mester","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George J.","family":"Kahaly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond S.","family":"Douglas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,6,28]]},"reference":[{"key":"1539_CR1","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1056\/NEJMra0905750","volume":"362","author":"RS Bahn","year":"2010","unstructured":"Bahn RS. Graves\u2019 ophthalmopathy. N Engl J Med. 2010;362:726\u201338.","journal-title":"N Engl J Med."},{"key":"1539_CR2","doi-asserted-by":"publisher","first-page":"4454","DOI":"10.1210\/jc.2012-2389","volume":"97","author":"L Bartalena","year":"2012","unstructured":"Bartalena L, Krassas GE, Wiersinga W, Marcocci C, Salvi M, Daumerie C, et al. Efficacy and safety of three different cumulative doses of intravenous methylprednisolone for moderate to severe and active Graves\u2019 orbitopathy. J Clin Endocrinol Metab. 2012;97:4454\u201363.","journal-title":"J Clin Endocrinol Metab."},{"key":"1539_CR3","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1210\/jc.2014-2572","volume":"100","author":"MN Stan","year":"2015","unstructured":"Stan MN, Garrity JA, Leon BGC, Prabin T, Bradley EA, Bahn RS. Randomized controlled trial of rituximab in patients with graves\u2019 orbitopathy. J Clin Endocrinol Metab. 2015;100:432\u201341.","journal-title":"J Clin Endocrinol Metab."},{"key":"1539_CR4","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.ajo.2018.07.038","volume":"195","author":"JV Perez-Moreiras","year":"2018","unstructured":"Perez-Moreiras JV, Gomez-Reino JJ, Maneiro JR, Perez-Pampin E, Romo Lopez A, Rodr\u00edguez, et al. Efficacy of tocilizumab in patients with moderate-to-severe corticosteroid-resistant graves orbitopathy: a randomized clinical trial. Am J Ophthalmol. 2018;195:181\u201390.","journal-title":"Am J Ophthalmol."},{"key":"1539_CR5","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.ajo.2019.07.021","volume":"208","author":"A Patel","year":"2019","unstructured":"Patel A, Yang H, Douglas RS. A new era in the treatment of thyroid eye disease. Am J Ophthalmol. 2019;208:281\u20138.","journal-title":"Am J Ophthalmol."},{"key":"1539_CR6","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.2147\/TCRM.S193018","volume":"15","author":"Y Wang","year":"2019","unstructured":"Wang Y, Patel A, Douglas RS. Thyroid eye disease: how a novel therapy may change the treatment paradigm. Ther Clin Risk Manag. 2019;15:1305\u201318.","journal-title":"Ther Clin Risk Manag."},{"key":"1539_CR7","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s40123-020-00318-x","volume":"10","author":"Y Wang","year":"2021","unstructured":"Wang Y, Sharma A, Padnick-Silver L, Francis-Sedlak M, Holt RJ, Foley C, et al. Physician-Perceived Impact of Thyroid Eye Disease on Patient Quality of Life in the United States. Ophthalmol. Ther. 2021;10:75\u201387.","journal-title":"Ophthalmol. Ther"},{"key":"1539_CR8","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1124\/pr.109.002469","volume":"62","author":"TJ Smith","year":"2010","unstructured":"Smith TJ. Insulin-like growth factor-I regulation of immune function: a potential therapeutic target in autoimmune diseases? Pharmacol Rev. 2010;62:199\u2013236.","journal-title":"Pharmacol Rev."},{"key":"1539_CR9","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1210\/jc.2014-3566","volume":"100","author":"CC Krieger","year":"2015","unstructured":"Krieger CC, Neumann S, Place RF, Marcus-Samuels B, Gershengorn MC. Bidirectional TSH and IGF-1 receptor cross talk mediates stimulation of hyaluronan secretion by Graves\u2019 disease immunoglobins. J Clin Endocrinol Metab. 2015;100:1071\u20137.","journal-title":"J Clin Endocrinol Metab."},{"key":"1539_CR10","doi-asserted-by":"publisher","first-page":"5076","DOI":"10.1210\/jc.2004-0716","volume":"89","author":"TJ Smith","year":"2004","unstructured":"Smith TJ, Hoa N. Immunoglobulins from patients with Graves\u2019 disease induce hyaluronan synthesis in their orbital fibroblasts through the self-antigen, insulin-like growth factor-I receptor. J Clin Endocrinol Metab. 2004;89:5076\u201380.","journal-title":"J Clin Endocrinol Metab."},{"key":"1539_CR11","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1677\/joe.0.1490351","volume":"149","author":"R Kooijman","year":"1996","unstructured":"Kooijman R, Rijkers GT, Zegers BJM. IGF-I potentiates interleukin-2 production in human peripheral T cells. J Endocrinol. 1996;149:351\u20136.","journal-title":"J Endocrinol."},{"key":"1539_CR12","doi-asserted-by":"publisher","first-page":"4611","DOI":"10.1210\/endo.137.11.8895324","volume":"137","author":"G Renier","year":"1996","unstructured":"Renier G, Cl\u00e9ment I, Desfaits AC, Lambert A. Direct stimulatory effect of insulin-like growth factor-I on monocyte and macrophage tumor necrosis factor-\u03b1 production. Endocrinology. 1996;137:4611\u20138.","journal-title":"Endocrinology."},{"key":"1539_CR13","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1016\/S0898-6568(03)00069-X","volume":"15","author":"R Kooijman","year":"2003","unstructured":"Kooijman R, Coppens A, Hooghe-Peters E. IGF-I stimulates IL-8 production in the promyelocytic cell line HL-60 through activation of extracellular signal-regulated protein kinase. Cell Signal. 2003;15:1091\u20138.","journal-title":"Cell Signal."},{"key":"1539_CR14","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1007\/s40265-020-01287-y","volume":"80","author":"A Markham","year":"2020","unstructured":"Markham A. Teprotumumab: first approval. Drugs. 2020;80:509\u201312.","journal-title":"Drugs."},{"key":"1539_CR15","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.1056\/NEJMoa1614949","volume":"376","author":"TJ Smith","year":"2017","unstructured":"Smith TJ, Kahaly GJ, Ezra DG, Fleming JC, Dailey RA, Tang RA, et al. Teprotumumab for thyroid-associated ophthalmopathy. N Engl J Med. 2017;376:1748\u201361.","journal-title":"N Engl J Med"},{"key":"1539_CR16","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1056\/NEJMoa1910434","volume":"382","author":"RS Douglas","year":"2020","unstructured":"Douglas RS, Kahaly GJ, Patel A, Sile S, Thompson EHZ, Perdok R, et al. Teprotumumab for the treatment of active thyroid eye disease. N Engl J Med. 2020;382:341\u201352.","journal-title":"N Engl J Med"},{"key":"1539_CR17","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1530\/EJE-07-0666","volume":"158","author":"L Bartalena","year":"2008","unstructured":"Bartalena L, Baldeschi L, Dickinson A, Eckstein A, Kendall-Taylor P, Marcocci C, et al. Consensus statement of the European Group on Graves\u2019 orbitopathy (EUGOGO) on management of GO. Eur J Endocrinol. 2008;158:273\u201385. http:\/\/ovidsp.ovid.com\/ovidweb.cgi?T=JS&PAGE=reference&D=emed10&NEWS=N&AN=351404990.","journal-title":"Eur J Endocrinol"},{"key":"1539_CR18","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1136\/bjo.73.8.639","volume":"73","author":"MP Mourits","year":"1989","unstructured":"Mourits MP, Koornneef L, Wiersinga WM, Prummel MF, Berghout A, van der Gaag R. Clinical criteria for the assessment of disease activity in Graves\u2019 ophthalmopathy: a novel approach. Br J Ophthalmol. 1989;73:639\u201344.","journal-title":"Br J Ophthalmol."},{"key":"1539_CR19","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1210\/er.2006-0001","volume":"28","author":"AA Samani","year":"2007","unstructured":"Samani AA, Yakar S, LeRoith D, Brodt P. The role of the IGF system in cancer growth and metastasis: overview and recent insights. Endocr Rev. 2007;28:20\u201347.","journal-title":"Endocr Rev."},{"key":"1539_CR20","doi-asserted-by":"publisher","first-page":"5038","DOI":"10.1016\/S0021-9258(18)34631-3","volume":"257","author":"J Massague","year":"1982","unstructured":"Massague J, Czech MP. The subunit structures of two distinct receptors for insulin-like growth factors I and II and their relationship to the insulin receptor. J Biol Chem. 1982;257:5038\u201345.","journal-title":"J Biol Chem."},{"key":"1539_CR21","doi-asserted-by":"publisher","first-page":"11486","DOI":"10.1016\/S0021-9258(18)37983-3","volume":"263","author":"G Steele-Perkins","year":"1988","unstructured":"Steele-Perkins G, Turner J, Edman JC, Hari J, Pierce SB, Stover C, et al. Expression and characterization of a functional human insulin-like growth factor I receptor. J Biol Chem. 1988;263:11486\u201392.","journal-title":"J Biol Chem."},{"key":"1539_CR22","doi-asserted-by":"crossref","unstructured":"Varewijck AJ, Janssen JAMJL. Insulin and its analogues and their affinities for the IGF1 receptor. Endocr Relat Cancer. 2012; 19.","DOI":"10.1530\/ERC-12-0026"},{"key":"1539_CR23","doi-asserted-by":"publisher","first-page":"14","DOI":"10.2174\/157489212798357930","volume":"7","author":"E R King","year":"2011","unstructured":"R King E, Wong K-K. Insulin-like growth factor: current concepts and new developments in cancer therapy. Recent Pat Anticancer Drug Discov. 2011;7:14\u201330.","journal-title":"Recent Pat Anticancer Drug Discov."}],"container-title":["Eye"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41433-021-01539-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-021-01539-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-021-01539-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,24]],"date-time":"2022-06-24T14:11:43Z","timestamp":1656079903000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41433-021-01539-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,28]]},"references-count":23,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["1539"],"URL":"https:\/\/doi.org\/10.1038\/s41433-021-01539-5","relation":{},"ISSN":["0950-222X","1476-5454"],"issn-type":[{"value":"0950-222X","type":"print"},{"value":"1476-5454","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,28]]},"assertion":[{"value":"1 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 June 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"RSD\u2014Consultant Horizon Therapeutics, Immunovant. The JGU Medical Center has received research-associated funding from Horizon Therapeutics.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}